Antonetti Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Antonetti Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$17.7K	Hold	390	–	–	0.03%	169
2023 Q2	$21.9K	Hold	390	–	–	0.03%	155
2023 Q1	$17.6K	Hold	390	–	–	0.03%	179
2022 Q4	$15.9K	Hold	390	–	–	0.02%	192
2022 Q3	$25K	Sell	390 -1,250	-76%	-$90.6K	0.03%	142
2022 Q2	$100K	Buy	1,640 +450	+38%	+$26.5K	0.11%	68
2022 Q1	$75K	Hold	1,190	–	–	0.07%	90
2021 Q4	$90K	Buy	1,190 +165	+16%	+$14.4K	0.07%	122
2021 Q3	$115K	Buy	+1,025	New	+$129K	0.09%	111

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Antonetti Capital Management's CRSP Position: Q3 2023 in Review

Antonetti Capital Management held its CRISPR Therapeutics (CRSP) position steady in Q3 2023 at 390 shares worth $17.7K. The position accounts for 0.03% of the portfolio, ranked #169.

Antonetti Capital Management first reported a position in CRSP in Q3 2021 and has held it in 9 quarters since. The position peaked at $115K in Q3 2021. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

Antonetti Capital Management held 390 shares of CRISPR Therapeutics worth $17.7K as of Q3 2023.
Antonetti Capital Management left its CRISPR Therapeutics share count unchanged in Q3 2023.
CRISPR Therapeutics made up 0.03% of Antonetti Capital Management's portfolio in Q3 2023, its #169 holding.
Antonetti Capital Management first reported a position in CRISPR Therapeutics in Q3 2021 and has held it in 9 quarters since.
Antonetti Capital Management's CRISPR Therapeutics position peaked at $115K in Q3 2021.
406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Antonetti Capital Management's 13F filing for Q3 2023, filed 9 Nov 2023.